Skip to content
Business Company News, Oil Mining Resources

Euro Manganese (TSX-V and ASX:EMN) Submits Application for Strategic Project Status Under EU’s Critical Raw Materials Act

Jane Morgan Management 2 mins read

Vancouver, British Columbia – 29 August 2024 | Euro Manganese Inc. (TSX-V and ASX:EMN; OTCQB:EUMNF; Frankfurt:E06) ("Euro Manganese" or the "Company") is pleased to announce that it has submitted an application to designate the Chvaletice Manganese Project ("Chvaletice Project" or the "Project") as a “Strategic Project” under the European Union’s (“EU”) Critical Raw Materials Act (“CRMA”).

Highlights:

  • “Strategic Project” Application: Euro Manganese has applied for Strategic Project status for the Chvaletice Manganese Project under EU’s CRMA – legislation designed to ensure sustainable availability of raw essential materials that are crucial to European economies and a clean/green transition.

  • Strategic Project Recognition: Achieving a Strategic Project designation could provide the Company with access to financing via a variety of potential private and public sources. This could include large EU institutions, national European banks, and even private financial institutions. This status also ensures that permitting processes are streamlined according to CRMA deadlines, reducing scheduling risks.

  • Timeline for Decision: The European Commission is expected to announce the first list of Strategic Projects in December 2024, which could include the Chvaletice Project if the application is successful.

Dr. Matthew James, President & CEO of Euro Manganese, commented

“Submitting our application for Strategic Project status under the CRMA for the Chvaletice Project is a significant milestone for Euro Manganese. Achieving Strategic Project designation would strengthen our role in the EU’s raw materials value chain, enable access to government-backed funding, facilitate collaboration with EU institutions, and accelerate permitting. Today’s announcement underscores our commitment to becoming the only integrated European producer of high-purity manganese for the battery supply chain.”

About Chvaletice Manganese Project:

The Chvaletice Manganese Project is a waste-to-value recycling and remediation opportunity involving the reprocessing of old tailings from a decommissioned mine. Situated in the Czech Republic, it is the only sizable resource of manganese in the EU, positioning Euro Manganese to contribute to the battery supply chain, which is essential for the shift to a circular, lowwer-carbon economy.

Dr. Matthew James
President & CEO
mjames@mn25.ca

Neil Weber
Investor and Media Relations – North America
+1 (647) 222-0574
neil.weber@loderockadvisors.com

Jane Morgan
Investor and Media Relations – Australia
+61 (0) 405 555 618
jm@janemorganmanagement.com.au


About us:

About Euro Manganese:

Euro Manganese is a battery materials company focused on becoming a leading producer of high-purity manganese for the electric vehicle industry. The Company is advancing development of the Chvaletice Manganese Project in the Czech Republic and exploring an early-stage opportunity to produce battery-grade manganese products in Bécancour, Québec. 

The Chvaletice Project is a unique waste-to-value recycling and remediation opportunity involving reprocessing old tailings from a decommissioned mine. It is also the only sizable resource of manganese in the European Union, strategically positioning the Company to provide battery supply chains with critical raw materials to support the global shift to a circular, low-carbon economy. 


Contact details:

Jane Morgan
Investor and Media Relations – Australia
+61 (0) 405 555 618
jm@janemorganmanagement.com.au

Media

More from this category

  • Business Company News
  • 22/01/2025
  • 19:11
ZeroPath Corp

ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence

ZeroPath Security Scanner Launches to Market, Bringing Enterprise-Grade AI Security Analysis to Development Teams SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / ZeroPath Corp., a Y Combinator-backed cybersecurity company, today announced the public launch of its LLM-driven code security platform. The company was previously noted for using its platform to find critical zero-day vulnerabilities in major open-source projects. Alongside the launch, the company also announced the completion of its seed funding round led by SurgePoint Capital, with Y Combinator and angel investor Paul Graham both participating. ZeroPath's security testing platform, among the first of its kind, attempts…

  • Business Company News
  • 22/01/2025
  • 13:22
Monash University

Monash Experts: How the Trump presidency may impact the Australian business landscape

Monash University experts are available to talk about how the executive orders US President Donald Trump has made on his first day in office may impact the Australian business landscape. Available for comment: Associate Professor Nathan Eva, Department of Management, Monash Business School Contact: +61 3 9903 4840 or media@monash.edu Comments attributable to Associate Professor Nathan Eva: “President Trump’s executive orders set a cultural precedent that I worry will filter through organisations worldwide. Rolling back diversity, equity and inclusion initiatives, removing work-from-home flexibility, changing the names of landmarks to be (White)-America-centric, ending the push for clean energy, and removing any…

  • Biotechnology, Business Company News
  • 22/01/2025
  • 09:41
Jane Morgan Management

LTR Pharma Limited (ASX:LTP) Signs National Pharmacy Distribution Agreement with Symbion, Establishing Nationwide Distribution Network for SPONTAN®

22 January 2025 – Sydney, Australia | ASX-listed LTR Pharma Limited (ASX:LTP) has announced a strategic partnership with Symbion Pty Ltd, which is one of the largest pharmaceutical wholesalers in Australia. This will facilitate the nationwide distribution of novel nasal spray treatment for Erectile Dysfunction (ED), SPONTAN®. The non-exclusive agreement, which commences on 1 March 2025, enables LTR Pharma to leverage Symbion's extensive network of over 3,900 pharmacies across the country. This collaboration will play a vital role in supporting the early access scheme that LTR will use and sets a new foundation for SPONTAN’s commercial launch following the appropriate…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.